MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sales and
maturities of investments
$759,425K
(35.61%↑ Y/Y)
Atm offering, net of
fees
$73,948K
(58.49%↑ Y/Y)
Proceeds from warrant and
option exercises and...
$2,491K
(-76.96%↓ Y/Y)
Net cash (used in)
provided by investing...
$341,388K
(161.69%↑ Y/Y)
Net cash provided by
financing activities
$76,439K
(-87.52%↓ Y/Y)
Canceled cashflow
$418,037K
Net (decrease)
increase in cash and cash...
$139,142K
(584.95%↑ Y/Y)
Canceled cashflow
$278,685K
Purchases of investments
$418,037K
(-62.45%↓ Y/Y)
Accounts payable
$43,438K
(1786.15%↑ Y/Y)
Stock-based compensation
$40,818K
(37.38%↑ Y/Y)
Accrued expenses
$6,168K
(6.05%↑ Y/Y)
Accrued interest, net of
interest receivable on...
-$5,076K
(-323.35%↓ Y/Y)
Amortization of right-of-use
assets
$431K
(24.57%↑ Y/Y)
Amortization of financing
costs
$56K
(-40.43%↓ Y/Y)
Interest expense related
to operating lease...
$10K
(-73.68%↓ Y/Y)
Net cash used in
operating activities
-$278,685K
(-217.45%↓ Y/Y)
Canceled cashflow
$95,997K
Net loss
-$359,639K
(-227.05%↓ Y/Y)
(accretion) amortization of
investment premiums
$9,284K
(-46.23%↓ Y/Y)
Prepaid expenses and
other current assets
$5,199K
(1265.70%↑ Y/Y)
Lease liability
-$505K
(-25.62%↓ Y/Y)
Realized gain on
investment
$55K
(-50.89%↓ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
viking_9_15_logo-svg
Viking Therapeutics, Inc. (VKTX)
viking_9_15_logo-svg
Viking Therapeutics, Inc. (VKTX)